Norges Bank’s Unity Biotechnology UBX Stock Holding History

Norges Bank’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,090	Closed	-$273K	–	2295
2021 Q3	$273K	Sell	9,090 -13,810	-60%	-$487K	﹤0.01%	2249
2021 Q2	$1.06M	Buy	+22,900	New	+$1.1M	﹤0.01%	2110

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Norges Bank's UBX Position: Q4 2021 in Review

Norges Bank sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 9,090 shares — an estimated $273K sold.

Norges Bank first reported a position in UBX in Q2 2021 and held it in 2 quarters. The position peaked at $1.06M in Q2 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

Norges Bank reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
Norges Bank sold 9,090 Unity Biotechnology shares in Q4 2021, an estimated $273K.
Norges Bank first reported a position in Unity Biotechnology in Q2 2021 and held it in 2 quarters.
Norges Bank's Unity Biotechnology position peaked at $1.06M in Q2 2021.
71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Norges Bank's 13F filing for Q4 2021, filed 10 Feb 2022.